Crinetics Pharmaceuticals, Inc. — Director's Dealing 2018

Jul 18, 2018

SEC Form 3 — Initial Statement of Beneficial Ownership

Issuer: Crinetics Pharmaceuticals, Inc. (CRNX)
CIK: 0001658247
Period of Report: 2018-07-17

Reporting Person: Kaldor Stephen W (Director)

Holdings (Derivative)

Security	Exercise Price	Expiration	Underlying	Shares	Ownership
Stock Option (right to buy)	$0.73	2025-12-10	Common Stock (54711)		Direct
Stock Option (right to buy)	$1.91	2028-03-16	Common Stock (15197)		Direct

Footnotes

F1: 25% of the shares subject to the option vested on October 30, 2016, and 1/48th of the shares subject to the option vest monthly thereafter, subject to the Reporting Person's continued service to the Issuer on each such vesting date. The shares subject to the option are also subject to accelerated vesting as set forth in the stock option agreement between the Issuer and the Reporting Person.

F2: The option is exercisable as to vested and unvested shares. 1/24th of the shares subject to the option vested on April 16, 2018, and 1/24th of the shares subject to the option vest monthly thereafter, subject to the Reporting Person's continued service to the Issuer on each such vesting date.